Personalis Reports Third Quarter Results - Yahoo Finance
Yahoo Finance · Nov 4, 9:01 PM
Personalis Reports Third Quarter Results - Business Wire
Business Wire · Nov 4, 9:01 PM
Personalis Advances Business Strategy with Investment from Merck and Extends Collaboration with Moderna - BioSpace
BioSpace · Nov 3, 2:46 AM
Personalis sells NeXT Personal, a blood test that tracks cancer's return, and genomic services to drug companies; it has agreed to be acquired by Tempus AI.
Personalis has agreed to be acquired by Tempus AI for $16.25 a share in Tempus stock. At or below a Tempus price of $48.42 the exchange ratio is fixed, so the value falls if Tempus trades lower. The antitrust waiting period expired on October 2, 2026, leaving the Personalis shareholder vote, whose date has not been set, as the main step. Merck, with about 13% of the vote, has agreed to vote in favor, and the outside date is April 20, 2027.
Thesis checklist
0 risks need attention
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Next decision point
Tests: Shareholders approve the merger
Do Personalis shareholders approve the Tempus merger?
Strong, inconclusive and weak outcomes
What to look for in the result and how each would move the checklist
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
Tempus's $16.25-a-share acquisition of Personalis cleared U.S. antitrust review in October; the shareholder vote is the main step left
Personalis's $1.5B all-stock Tempus acquisition: MRD platform finds a buyer, but deal closing conditions determine whether holders get paid
Medicare coverage cascade unlocks MRD commercial ramp, but $233M burns fast against $10M clinical revenue
About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.
Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.
Disease areas: Lung cancer, Breast and gynecologic cancers
Catalyst calendar · Upcoming FDA decisions · Thesis changes
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.